Talis Biomedical Corp Alpha and Beta Analysis
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Talis Biomedical Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Talis Biomedical over a specified time horizon. Remember, high Talis Biomedical's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Talis Biomedical's market risk premium analysis include:
Beta 0.95 | Alpha (1.98) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Talis |
Talis Biomedical Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Talis Biomedical market risk premium is the additional return an investor will receive from holding Talis Biomedical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Talis Biomedical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Talis Biomedical's performance over market.| α | -1.98 | β | 0.95 |
Talis Biomedical Fundamentals Vs Peers
Comparing Talis Biomedical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Talis Biomedical's direct or indirect competition across all of the common fundamentals between Talis Biomedical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Talis Biomedical or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Talis Biomedical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Talis Biomedical to competition |
| Fundamentals | Talis Biomedical | Peer Average |
| Return On Equity | -0.7 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Operating Margin | (113.60) % | (5.51) % |
| Current Valuation | (38.24 M) | 16.62 B |
| Shares Outstanding | 1.82 M | 571.82 M |
| Shares Owned By Insiders | 8.30 % | 10.09 % |
| Shares Owned By Institutions | 52.15 % | 39.21 % |
Talis Biomedical Opportunities
Talis Biomedical Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Talis Biomedical Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Talis or other pink sheets. Alpha measures the amount that position in Talis Biomedical Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Talis Biomedical Upcoming Company Events
As portrayed in its financial statements, the presentation of Talis Biomedical's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Talis Biomedical's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Talis Biomedical's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Talis Biomedical. Please utilize our Beneish M Score to check the likelihood of Talis Biomedical's management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Talis Biomedical
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |